

# Long-Term Effectiveness of Repeat Corticosteroid Injections for Trigger Finger

Agnes Z. Dardas, BA,\* James VandenBerg, BS,\* Tony Shen, BA,\*  
Richard H. Gelberman, MD,\* Ryan P. Calfee, MD, MSc\*

**Purpose** To quantify the long-term success of repeat injections for trigger fingers and to identify predictors of treatment outcomes.

**Methods** This retrospective case series analyzed 292 repeat corticosteroid injections for trigger fingers administered by hand surgeons at a single tertiary center between January 2010 and January 2013. One hundred eighty-seven patients (64%) were female, 139 patients (48%) had multiple trigger fingers, and 63 patients (22%) were diabetic. The primary outcome, treatment failure, was defined as receiving a subsequent injection or surgical treatment. Patients without either documented failure or a return office visit in 2015 or 2016 were surveyed by telephone to determine if they had required subsequent treatment. Kaplan-Meier analyses with log-rank testing assessed the median time to treatment failure and the effect of demographic and disease-specific characteristics on injection success rate and predictors of injection outcome (success vs failure) were assessed with multivariable logistic regression.

**Results** Second injections provided long-term treatment success in 39% (111 of 285) of trigger fingers with 86 receiving an additional injection and 108 ultimately undergoing surgical release. Thirty-nine percent (24 of 62) of third injections resulted in long-term success, with 22 receiving an additional injection, and 23 ultimately undergoing surgery. Median times-to-failure for second and third injections were 371 and 407 days, respectively. Success curves did not differ significantly according to any patient or disease factor. Logistic regression identified that advancing patient age and injection for trigger thumb were associated with success of second injections.

**Conclusions** Thirty-nine percent of second and third corticosteroid injections for trigger finger yield long-term relief. Although most patients ultimately require surgical release, 50% of patients receiving repeat trigger injections realize 1 year or more of symptomatic relief. Repeat injections of trigger fingers should be considered in patients who prefer nonsurgical treatment. (*J Hand Surg Am.* 2017;42(4):227–235. Copyright © 2017 by the American Society for Surgery of the Hand. All rights reserved.)

**Type of study/level of evidence** Therapeutic IV.

**Key words** Corticosteroid, injection, repeat, stenosing tenosynovitis, trigger finger.



\*From the Department of Orthopedic Surgery, Washington University School of Medicine, St. Louis, MO.

Received for publication September 30, 2016; accepted in revised form February 2, 2017.

Research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448, subaward TL1TR000449, from the National Center for Advancing Translational Sciences of the National Institutes of Health, and Siteman Comprehensive Cancer Center and National Cancer Institute Cancer Center Support Grant P30 CA091842, which supported the maintenance and use of REDCap electronic data capture tools, hosted in the Biostatistics Division of Washington University

School of Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. This funding did not play a direct role in this investigation.

**Corresponding author:** Ryan P. Calfee, MD, MSc, Department of Orthopedic Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8233, St. Louis, MO 63110; e-mail: [calfeer@wudosis.wustl.edu](mailto:calfeer@wudosis.wustl.edu).

0363-5023/17/4204-0001\$36.00/0  
<http://dx.doi.org/10.1016/j.jhssa.2017.02.001>

CORTICOSTEROID INJECTIONS ARE the definitive treatment for the majority of newly diagnosed trigger fingers.<sup>1–12</sup> The response to initial corticosteroid injections is well-studied, with the percentage of symptom-free patients gradually declining over the first year after injection before plateauing at 45% treatment success by 5 years.<sup>13,14</sup> Factors affecting the outcome after initial trigger finger injection include symptom duration,<sup>2,3</sup> nodule type,<sup>8</sup> finger involved,<sup>7,9</sup> presence of multiple trigger fingers,<sup>2,9,13,14</sup> sex,<sup>7,14</sup> age,<sup>13</sup> comorbid upper extremity tendonopathies,<sup>13</sup> and diabetes.<sup>15,16</sup>

The chance of long-term success after second and third injections for trigger finger is less precisely understood. Estimates for the chance of symptomatic relief ranges from 23% to 79% for second injections and from 6% to 74% for third injections.<sup>2,4,5,9,10,13,17</sup> These wide ranges reflect prior studies reporting these outcomes with secondary descriptive statistics as opposed to being evaluated as a primary research focus.

Based on the available literature, surgeons are unable to counsel patients precisely regarding the risk of symptom recurrence after a repeat corticosteroid injection. Furthermore, the pattern of symptom recurrence over time and the factors affecting treatment success remain unclear. This study was designed to quantify the likelihood of long-term success after second and third corticosteroid injections for trigger fingers. The secondary aim was to identify factors predictive of treatment success. Our working hypothesis was that the success of repeat injections would be less than initial injections and that factors associated with the success of initial injections (ie, multiple trigger fingers, diabetes) would have an impact on the chance of success with repeat injection.

## MATERIALS AND METHODS

### Participant selection

Our institutional review board approved this single-center retrospective case series, which analyzed 289 second and third corticosteroid injections in flexor tendon sheaths to quantify the chance of long-term success of repeat corticosteroid injections for trigger finger. Injections were placed into the flexor tendon sheath through the A1 pulley angled 45° from proximal to distal with 1 mL of 40 mg/mL methylprednisolone acetate (Depo-Medrol) and 0.5 to 1.0 mL of 1% lidocaine. The primary outcome, treatment failure, was defined as a subsequent


**TABLE 1. Green Classification of Trigger Finger Grade**

Grade I	Pain or tenderness at the A1 pulley
Grade II	Catching, can actively extend digit
Grade III	Locking, requiring passive extension
Grade IV	Locked, unable to passively extend, fixed flexion contracture

injection or surgical release of the A1 pulley of the affected digit.

Potential subjects treated for trigger finger by 1 of 7 fellowship-trained hand orthopedic surgeons at a single tertiary center between January 2010 and December 2013 were identified by a search of departmental billing data. The search was conducted using Current Procedural Terminology codes 20550 (injection; tendon sheath, ligament), 20551 (injection; tendon origin/insertion), or 20600 (arthrocentesis, aspiration, or injection) and *International Classification of Diseases*, Ninth Revision, codes 727.03 (trigger finger) or 727.05 (tenosynovitis; hand, wrist). Inclusion criteria required delivery of a repeat injection for trigger finger during the study period to a patient at least 18 years old. Our database search identified 2,176 injections in 1,483 patients over the study period.

Medical records were manually reviewed for the patient's age at first injection, sex, injection date, digit injected, symptoms graded according to the Green classification at each injection (Table 1), presence of multiple trigger fingers, and associated comorbidities with potential relevance to the trigger finger (ie, rheumatoid arthritis, hypothyroidism, carpal tunnel syndrome, other upper extremity tendonitis, and diabetes mellitus [non—insulin-dependent {NIDDM} vs insulin-dependent {IDDM}]) at time of injection. The presence of multiple trigger fingers was defined as more than 1 symptomatic trigger finger either at or before the time of repeat injection. For patients with return visits for treatment failure, the time to failure and subsequent treatment were recorded. For patients with repeat injections for multiple digits within the 3-year period, only the first repeat injection contributed data to the study to ensure independent observations for statistical analyses. In the case of concurrent bilateral injections, a random number generator was used to pick the studied side. This decision minimized bias introduced by the selection of a digit according to duration, severity, side, or subsequent treatment needed. Subjects were



**FIGURE 1:** Flow diagram of participant selection for study. OSH, outside hospital.

excluded if the medical record notes did not specify the digit injected ( $n = 131$ ).

Manual chart review identified 360 eligible patients (Fig. 1). Eligible subjects without documented failure who had not been seen in our office in June 2015 or later were contacted by telephone using 3 attempts with voicemails on separate days. Subjects were excluded at the time of the telephone call if they were unreachable ( $n = 44$ ), declined participation ( $n = 20$ ), had died ( $n = 0$ ), were unable to give study consent in English ( $n = 2$ ), could not recollect receiving a repeat injection for a trigger finger ( $n = 2$ ), or they stated that they received a later treatment but could not estimate the date within 1 month ( $n = 0$ ). Thus, 292 completed follow-up and were included in the final analysis. Follow-up data from telephone calls were collected after patients provided verbal consent for study participation. Patients were queried regarding recurrence of symptoms, dates of any necessary subsequent treatment, presence of other trigger fingers, and current diabetes status. Because patients who experience resolution of symptoms do not schedule routine follow-up visits in our practice, telephone follow-up minimized bias toward a lower estimated chance of treatment success associated with analyzing only patients who returned to the office as study subjects.

Among analyzed patients, 284 patients received second injections and 62 patients received third injections, with 54 patients receiving both during the specified period. The distribution of affected fingers

**TABLE 2. Baseline Population Characteristics (All Patients)**

Variables	Participants ( $n = 292$ ) $n$ (%)
Age at first Injection (y), (SD)	60 (11)
Sex, Female	187 (64)
Affected digit	
Thumb	79 (27)
Index	21 (7)
Middle	104 (36)
Ring	79 (27)
Small	9 (3)
Multiple triggers	139 (48)
Diabetes status at first injection	
None	229 (78)
NIDDM	41 (14)
IDDM	22 (8)
Comorbidities	
Rheumatoid arthritis	11 (4)
Hypothyroidism	40 (14)
Carpal tunnel syndrome	96 (33)
Upper extremity tendinitis	51 (18)

IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.

and patient demographic data are detailed in Table 2. Patients with successful injection who contributed data to this study had a minimum follow-up duration of 1.5 years.

**TABLE 3. Second Injection Characteristics and Bivariate Contrasts Between Successes and Failures**


Variables	Participants (n = 284) n (%)	Successes (n = 111) n (%)	Failures (n = 173) n (%)
Age at first injection (y), (SD)	60 (11)	61 (10)	59 (11)
Time between first and second injection (d), median (range)	217 (8–5,825)	235 (8–1,939)	210 (21–5,825)
Sex, female	183 (64)	79 (71)	104 (60)
Affected finger			
Thumb	78 (28)	41 (37)	37 (21)
Index	20 (7)	8 (7)	12 (7)
Middle	103 (36)	29 (26)	74 (43)
Ring	74 (26)	30 (27)	44 (25)
Little	9 (3)	3 (3)	6 (4)
Multiple triggers, yes	131 (46)	44 (40)	87 (50)
Diabetes status at first injection			
None	225 (79)	90 (81)	135 (78)
NIDDM	39 (14)	12 (11)	27 (16)
IDDM	20 (7)	9 (8)	11 (6)
Comorbidities			
Rheumatoid arthritis	11 (4)	4 (4)	7 (4)
Hypothyroidism	37 (13)	17 (15)	20 (12)
Carpal tunnel syndrome	93 (33)	33 (30)	60 (35)
Upper extremity tendinitis	48 (17)	22 (20)	26 (15)
Green classification at second injection (n = 242)			
Grade I	83 (34)	33 (34)	50 (35)
Grade II	147 (61)	60 (62)	87 (60)
Grade III	7 (3)	2 (2)	5 (3)
Grade IV	5 (2)	2 (2)	3 (2)

### Statistical analysis

Descriptive analyses produced frequencies and percentages for categorical variables and mean (SD) or median values for continuous variables. The median time to treatment failure was determined with Kaplan-Meier analysis. The effect of sex, multiple trigger fingers, and diabetes on the pattern of injection failure over time were tested with log-rank testing. Participants without treatment failure were censored at the time point corresponding to their most recent office visit or telephone follow-up. Bivariate analyses using chi-square or Fisher exact test for categorical variables and independent samples *t* test for continuous variables determined independent predictors of success. Multivariable logistic regression was used to model the relationship between treatment success and hypothesized predictors of success accounting for other patient characteristics. The presence of multiple trigger fingers (included

based on documented impact on success of initial trigger injection) and any other factors that approached significance during bivariate analysis were planned for inclusion in the multivariable logistic regression model for associations with the dependent outcome of treatment failure. A forward stepwise selection procedure was used with an alpha of 0.1 for entry. We assessed model explanatory power and fit using the Nagelkerke  $R^2$  and Hosmer-Lemeshow lack-of-fit test (confirmed  $P > .05$ ). An unadjusted alpha level of 0.05 for significance was used for all tests.

We chose the inclusive study dates to allow adequate sample size for multivariable testing to determine factors associated with success or failure of injections. Assuming at least a 50% chance of injection failure when planning this study, we determined the study interval to include 40 failures after second and third injections, respectively, to allow for



**FIGURE 2:** Kaplan-Meier curves for success after second and third injections for trigger fingers.

at least 4 predictor variables in our regression modeling. After data collection, we realized that the cohort of patients receiving third injections comprised small numbers of individuals when categorized by demographic and disease characteristics so multivariable testing was limited to the second injection cohort.

## RESULTS

### Second injections

Among the 284 patients who received second injections, 183 (64%) were female, with an average age of 60 years (SD, 11). One hundred thirty-one patients (46%) had multiple trigger fingers. Fifty-nine patients (21%) were diabetic, of which 39 had NIDDM and 20 had IDDM. The median time between initial and second injection was 214 days in patients without diabetes and 235 days in diabetic patients (366 days for IDDM, 213 days for NIDDM). Digits involved, trigger finger grade, and the presence of selected comorbidities are detailed in [Table 3](#).

Thirty-nine percent (111 of 284) were successfully treated with a second injection. One hundred seventy-three (61%) patients experienced treatment failure, with 86 patients (50%) receiving a subsequent third injection and 87 patients (50%) undergoing surgical release of the A1 pulley as the next treatment. As demonstrated in [Figure 2](#), the median time to treatment failure was 371 days (95% confidence interval [CI], 290–452). One hundred eight (62%) ultimately required a surgical release even after a subsequent injection

for symptomatic relief. Median time from injection to last follow-up, defined as either treatment failure or last follow-up if a success, for second injections was 371 days (range, 27–2 181 days). Median follow up for injections deemed successful without subsequent treatment was 1,325 days (range, 717–2,181 days). Sixty-nine percent (100 of 144) of patients requiring telephone follow-up reported treatment success.

### Third injections

Sixty-two patients were analyzed for third injections during the study period. Thirty-seven (60%) were female, with an average age of 60 years (SD, 10). Thirty-four patients (55%) had multiple trigger fingers. Eighteen patients (29%) were diabetic, of whom 12 were NIDDM and 6 were IDDM. [Table 4](#) presents the digits involved, trigger finger grade, and presence of selected comorbidities.

Thirty-nine percent (24 of 62) of patients receiving a third injection did not require further treatment. Thirty-eight patients (61%) experienced treatment failure, with 22 patients (59%) receiving a fourth subsequent injection and 16 patients (42%) undergoing surgical release of the A1 pulley as their next treatment. In total, 23 patients (61%) ultimately required a surgical release. Median time to treatment failure was 407 days, 95% CI [222–592] ([Fig. 2](#)). Median time from injection to last follow-up for third injections was 436 days (range, 62–2,027 days). Median follow up for injections deemed success without subsequent treatment was 1,317 days (range, 767–2,027 days). Of the 20 patients requiring telephone follow-up, 16 (80%) reported treatment success.

### Factors affecting treatment success

Bivariate testing demonstrated that sex, trigger finger grade, diabetes status, presence of multiple trigger fingers, and select comorbidities were not associated with success of second or third injections ([Tables 3, 4](#)). Log-rank analyses did not reveal any differences in success curves for patients receiving second or third injections according to sex, presence of multiple trigger fingers, or diabetes status. Multivariable logistic regression modeling revealed that, for second injections, older patient age at the time of initial injection ( $P < .05$ ; odds ratio, 1.03; 95% CI, 1.00–1.05) and trigger thumb ( $P < .05$ ; odds ratio, 2.47; 95% CI, 1.4–4.3) significantly predicted injection success while accounting for time between first and second injection, diabetes, sex and multiple trigger fingers.



**TABLE 4. Third Injection Characteristics and Bivariate Contrasts Between Successes and Failures**

Variables	Participants (n = 62)	Successes (n = 24)	Failures (n = 38)	P Value
	Mean (SD) n (%)	Mean (SD) n (%)	Mean (SD) n (%)	
Age at first injection, y	60 (10)	58 (9)	61 (10)	.30
Sex, female	37 (60)	17 (71)	20 (53)	.16
Affected finger				.53
Thumb	16 (26)	8 (33)	8 (21)	
Index	7 (11)	3 (13)	4 (11)	
Middle	18 (29)	6 (25)	12 (32)	
Ring	20 (32)	6 (25)	14 (37)	
Little	1 (2)	1 (4)	0 (0)	
Multiple triggers	34 (55)	13 (54)	21 (55)	.93
Diabetes status at first injection				.10
None	44 (71)	14 (58)	30 (79)	
NIDDM	12 (19)	8 (33)	4 (11)	
IDDM	6 (10)	2 (8)	4 (11)	
Comorbidities				
Rheumatoid arthritis	3 (5)	1 (4)	2 (5)	
Hypothyroidism	8 (13)	2 (8)	6 (16)	
Carpal tunnel syndrome	26 (42)	12 (50)	14 (37)	
Upper extremity tendinitis	9 (15)	3 (13)	6 (16)	
Green classification at third injection (n = 43)				.89
Grade I	11 (26)	5 (29)	6 (23)	
Grade II	24 (56)	10 (59)	14 (54)	
Grade III	4 (9)	1 (6)	3 (12)	
Grade IV	4 (9)	1 (6)	3 (12)	

## DISCUSSION

Our data confirm that 39% of patients who fail a first or second corticosteroid injection for trigger finger may respond to a subsequent steroid injection. Published literature has suggested that repeat injections for trigger fingers offer some benefit but are less effective than initial injections. Clark et al<sup>4</sup> found a 55% chance of success after 1 injection improved to 82% with several injections after an average follow-up of 44 months. Reporting similar experiences, Rhoades et al<sup>3</sup> reported 66% success after 1 injection and a 72% cumulative chance of success after multiple injections at 25 months, and Newport et al<sup>2</sup> reported a 49% chance of success after an initial injection and a combined success percentage of 77% for patients receiving up to 5 injections with an average follow-up of 35 months. Despite a wide range of follow-up duration and ultimate number of injections provided, multiple investigators have confirmed this finding of additional marginal

benefit of repeat steroid injections for trigger fingers.<sup>5,6,9-11,13,17,18</sup> Consistent with these publications, our current study's 39% chance of success after second and third injections yields a hypothetical 82% cumulative success rate after 3 injections when combined with our center's previously reported initial injection success rate of 45%.<sup>14</sup>

The 39% of patients realizing success after second and third injections in this study fall within the wide range reported in the literature for repeat injections (Table 5). Variability in the chances for success among studies may be attributed to variable duration of follow-up and methodological differences. Studies have inconsistently excluded patients with inflammatory arthritis<sup>13</sup> and the corticosteroid type and dose administered varies. Furthermore, the definition of treatment failure is not standard, frequently cited as either symptom recurrence or need for subsequent intervention. Schubert et al<sup>10</sup> reported a mean duration of relief after second and third injections with

**TABLE 5. Reported Success After Repeat Injections**

Study	Study Design	Trigger Fingers Analyzed (n)	Definition of Failure	Second Injection Success (%)	Third Injection Success (%)	Duration of Follow-Up, Median (Range)
Clark et al <sup>4</sup>	Retrospective	76	Return of symptoms	33	50	44 mo
Newport et al <sup>2</sup>	Retrospective	356	No improvement in symptoms	23	5*	35 mo (11–105 mo)
Anderson & Kaye <sup>5</sup>	Prospective	77	Return of symptoms	59	—	4.6 y
Benson & Ptaszek <sup>17</sup>	Retrospective	109	Return of symptoms	36	33	18 mo
Rozental et al <sup>13</sup>	Prospective	124	Surgical release	79	—	12.6 mo (12.1–13.2 mo)
Dala-Ali et al <sup>9</sup>	Retrospective	90	Injection or surgery	44	6	1 y minimum
Schubert et al <sup>10</sup>	Retrospective	577	Injection or surgery	52	74	66.4 mo (2–152 mo)
Castellanos et al <sup>11</sup>	Prospective	71	Return of symptoms	68		8 y (7–8 y)

\*5% for 3–5 injections.

8 mg of triamcinolone (300 and 286 days, respectively) was completed with an average follow-up of 66 months (range, 2–152 months). Whereas our study found a longer median time to failure of 371 and 407 days for a second and third injection, it is unclear if this is attributable to differences in patient demographics or to the steroid preparation.

Studies investigating patient and disease factors associated with success of corticosteroid injections for trigger fingers have focused on patients with initial injections or a mixed group of multiple injections, without specific analysis of repeat injections. Factors documented to affect injection success include duration of symptoms less than 4 months<sup>3</sup> and greater than 6 months,<sup>2</sup> sex,<sup>7,14</sup> finger type,<sup>7,9</sup> nodular subtype,<sup>8</sup> presence of multiple trigger fingers,<sup>2,9,13,14</sup> younger patient age,<sup>13</sup> and history of upper extremity tendonopathies.<sup>13</sup> Diabetes has also been proposed as a factor related to ultimate need for surgical release,<sup>13,15,16</sup> although this may be partly confounded by an increased presence of multiple trigger fingers. We considered these potential predictors of injection success in our current study. However, our data only indicated that successful second injection is associated with treatment for trigger thumb and that there is a small but significant positive impact of advancing patient age at the time of presentation for injection. We had expected diabetes to predict repeat injection failure. When our data did not substantiate this, we reexamined the time between first and second injection. Median time to second injection in diabetic patients was 235 days

(366 days for IDDM patients). This indicates that, although diabetes may predict failure of first injections for trigger finger, those diabetic patients receiving repeat injections are a subgroup that realized often prolonged symptom relief before recurrence prompting repeat injection. Presumably, diabetic patients who experienced no initial response, or very brief response, to first injection were more likely to be offered surgery as opposed to repeat injection. This selection bias affecting patients with diabetes may explain why this group experienced relief similar to that of unaffected patients after second injection. The increased chance of success for injection to the thumb in comparison with other digits was also found in the reports of Marks and Gunther<sup>7</sup> and Castellanos et al.<sup>11</sup> Although the reason for this is unclear, we hypothesize that this difference may be attributable to the isolated flexor pollicis longus with the thumb flexor sheath versus the other digits where the flexor digitorum superficialis and profundus must both glide within each flexor sheath.<sup>11</sup>

The relative paucity of published data specifically examining the outcomes after repeat corticosteroid injections for trigger fingers may affect hand surgeon's practice patterns. Whereas corticosteroid injections remain a physician's first choice for initial treatment of trigger finger, there is considerable variation as to whether providers offer a repeat injection, especially if a patient has already received 2 injections. A recent online survey of the American Association of Hand Surgeons members (139 respondents) found that only 11% and 13% of

physicians reported giving 3 or more injections for trigger thumb and finger, respectively, prior to recommending surgery.<sup>19</sup> This was consistent with a national database study assessing 102,778 records for treatments of trigger fingers finding that only 16% of which received at least 3 injections.<sup>20</sup> Based on a presumed minimal chance of third injection to prevent surgery, a cost-minimization analysis by Kerrigan and Stanwix<sup>21</sup> determined that the optimal treatment strategy for recurrent trigger finger was 2 steroid injections followed by surgery. This same analysis found that the third injections would have to provide 9% or more of patients with long-term relief to be the most cost-effective treatment.<sup>21</sup> Given patients' preference for corticosteroid injections over surgery,<sup>22</sup> Kerrigan and Stanwix's cost-minimization analysis,<sup>21</sup> and this study's 39% success rate for third injections, changes in practice patterns incorporating a 3-injection treatment algorithm may be more cost-effective for providers and deliver care in accordance with patient preferences.

Several limitations are inherent to this study's design. We defined treatment failure as a repeat injection or surgery rather than recurrence of symptoms. This should detect clinically relevant symptoms prompting patients to seek care but presumably underestimates the percentage of patients with mild persistent symptoms. We did not control for adjunctive nonsurgical management such as orthosis fabrication, therapy, or nonsteroidal anti-inflammatory drugs. These are not specifically prescribed by our providers but are not prohibited. We designed the study to call all patients without a follow-up in the last 6 months to mitigate selection bias. Chart review alone would have disproportionately selected patients with symptom recurrence seeking treatment biasing the study toward a lower estimate of treatment success. Nevertheless, 68 patients, all of whom only received second injections, were lost to follow-up. Assuming that these patients had the same percentage of success as others contacted by phone, a sensitivity analysis incorporating those lost to follow-up would result in an adjusted chance of treatment success after second injections from 39% to 45%. We chose to include patients who had seen an outside provider for their initial injection because this did not detract from analysis of repeat injections (all performed within our division) and more broadly reflects our practice experience, thereby increasing external validity. We could not assess the outcome of 4 or more injections for any trigger finger because our practice is to avoid that number of injections secondary to the theoretical risk of injection-related

tendon damage. Finally, because some patients contributed data to both the second and the third injection groups, we did not perform any analysis that would combine these groups so that all injections remained independent events for statistical contrasts.

Second and third injections for trigger finger each provide sustained relief that may prevent the need for surgery. Although the majority of patients ultimately require surgical release, we believe our data support our practice of offering up to 3 injections for persistent or recurrent trigger fingers. We offer surgical intervention after failure of an initial injection but inform patients about the expected chance of success associated with repeat injection and honor the patient's desire for either continued nonsurgical or surgical treatment.

## REFERENCES

1. Patel MR, Bassini L. Trigger fingers and thumb: when to splint, inject, or operate. *J Hand Surg Am.* 1992;17(1):110–113.
2. Newport M, Lane L, Stuchin S. Treatment of trigger finger by steroid injection. *J Hand Surg Am.* 1990;15(5):748–750.
3. Rhoades CE, Gelberman RH, Manjarris JF. Stenosing tenosynovitis of the fingers and thumb. Results of a prospective trial of steroid injection and splinting. *Clin Orthop Relat Res.* 1984;190:236–238.
4. Clark DD, Ricker JH, MacCollum MS. The efficacy of local steroid injection in the treatment of stenosing tenovaginitis. *Plast Reconstr Surg.* 1973;51(2):179–180.
5. Anderson B, Kaye S. Treatment of flexor tenosynovitis of the hand ("trigger finger") with corticosteroids. A prospective study of the response to local injection. *Arch Intern Med.* 1991;151(1):153–156.
6. Faunø P, Andersen HJ, Simonsen O. A long-term follow-up of the effect of repeated corticosteroid injections for stenosing tenovaginitis. *J Hand Surg Br.* 1989;14(2):242–243.
7. Marks M, Gunther S. Efficacy of cortisone injection in treatment of trigger fingers and thumbs. *J Hand Surg Am.* 1989;14(4):722–727.
8. Freiberg A, Mulholland R, Levine R. Nonoperative treatment of trigger fingers and thumbs. *J Hand Surg Am.* 1989;14(3):553–558.
9. Dala-Ali B, Nakhdehvari A, Lloyd M, Schreuder F. The efficacy of steroid injection in the treatment of trigger finger. *Clin Orthop Surg.* 2012;4(4):263–268.
10. Schubert C, Hui-Chou HG, See AP, Deune EG. Corticosteroid injection therapy for trigger finger or thumb: a retrospective review of 577 digits. *Hand (N Y).* 2013;8(4):439–444.
11. Castellanos J, Munoz-Mahamud E, Dominguez E, Del Amo P, Izquierdo O, Fillat P. Long-term effectiveness of corticosteroid injections for trigger finger and thumb. *J Hand Surg Am.* 2015;40(1):121–126.
12. Sato E, Gomes dos Santos J, Belloti J, Albertoni W, Faloppa F. Treatment of trigger finger: randomized clinical trial comparing the methods of corticosteroid injection, percutaneous release and open surgery. *Rheumatology (Oxford).* 2012;51(1):93–99.
13. Rozental T, Zurakowski D, Blazar P. Trigger finger: prognostic indicators of recurrence following corticosteroid injection. *J Bone Jt Surg Am.* 2008;90(8):1665–1672.
14. Wojahn R, Foeger N, Gelberman R, Calfee R. Long-term outcomes following a single corticosteroid injection for trigger finger. *J Bone Jt Surg Am.* 2014;96(22):1849–1854.
15. Sheikh E, Peters J, Sayde W, Maltenfort M, Leinberry C. A prospective randomized trial comparing the effectiveness of one versus two (staged) corticosteroid injections for the treatment of stenosing tenosynovitis. *Hand (N Y).* 2014;9(3):340–345.



16. Baumgarten K, Gerlach D, Boyer M. Corticosteroid injection in diabetic patients with trigger finger. A prospective, randomized, controlled double-blinded study. *J Bone Jt Surg Am.* 2007;89(12):2604–2611.
17. Benson L, Ptaszek A. Injection versus surgery in the treatment of trigger finger. *J Hand Surg Am.* 1997;22(1):138–144.
18. Nimigan A, Ross D, Gan B. Steroid injections in the management of trigger fingers. *Am J Phys Med Rehabil.* 2006;85(1):36–43.
19. Pruzansky J, Goljan P, Lundmark D, Shin E, Jacoby S, Osterman A. Treatment preferences for trigger digit by members of the American Association for Hand Surgery. *Hand (N Y).* 2014;9(4):529–533.
20. Sears E, Swiatek P, Chung K. National utilization patterns of steroid injection and operative intervention for treatment of common hand conditions. *J Hand Surg Am.* 2016;41(3):367–373.
21. Kerrigan CL, Stanwix MG. Using evidence to minimize the cost of trigger finger care. *J Hand Surg Am.* 2009;34(6):997–1005.
22. Doring A, Hageman M, Mulder F, Guitton T, Ring D. Science of Variation Group. Trigger finger: assessment of surgeon and patient preferences and priorities for decision making. *J Hand Surg Am.* 2014;39(11):2208–2213.e2.